Chemical Structure (Duloxetine 01)
Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 63629-2063
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63629-2063). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Duloxetine 02)
The text is a chart showing the proportion of patients with relapse over time from randomization to relapse, for two different treatments: placebo and Duloxetine delayed-release capsules. The chart suggests that the Duloxetine delayed-release capsules treatment may be more effective in reducing relapse compared to placebo.*
Figure 2 (Duloxetine 03)
The text appears to be a graph showing the proportion of patients with relapse over time from randomization to relapse in days. The graph compares the effectiveness of a placebo versus Duloxetine delayed-release capsules in treating the condition.*
Figure 3 (Duloxetine 04)
Figure 4 (Duloxetine 05)
Figure 5 (Duloxetine 06)
Figure 6 (Duloxetine 07)
Figure 8 (Duloxetine 08)
The given text seems to be a graph that displays the percentage of patients improved with the treatment of Placebo and DUL 60/120 mg once daily. The X-axis represents the percent improvement in pain from the baseline while the Y-axis represents the number of patients. However, the graph is not completely clear due to missing axis labels and other relevant details.*
Figure 9 (Duloxetine 09)
The text refers to a graph or table that shows the percentage of patients who improved after taking a placebo or a 60mg dose of DUL once daily. The table shows that 88% of patients taking a placebo improved, while 100% of patients taking DUL 60mg improved. Additionally, there is a line graph showing the percentage improvement in pain from a baseline score. However, the text does not provide enough context to understand the specifics of the graph or table, and the numbers provided appear to be incomplete or lacking full context. Therefore, a more detailed description cannot be provided.*
Figure 10 (Duloxetine 10)
This is a graph showing the percentage of patient improvement in pain from baseline (BOCF) for a placebo group and a group taking DUL60/120 mg once daily. The graph shows different percentages of improvement ranging from 0% to over 80%.*
Label (Lbl636292063)
This is a medication called NILD, specifically duloxetine hydrochloride delayed release capsules. Each capsule has 40mg of the active ingredient. It is important to keep this medication out of the reach of children and store it in a secure location at room temperature. The medication should be dispensed in a tightly sealed container that protects it from light. The NDC number is 63629-2063-1 and it is an Rx-only medication, with 30 capsules per container.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
